DE69322860T2 - Antikörper gegen alpha v beta 3 integrin - Google Patents

Antikörper gegen alpha v beta 3 integrin

Info

Publication number
DE69322860T2
DE69322860T2 DE69322860T DE69322860T DE69322860T2 DE 69322860 T2 DE69322860 T2 DE 69322860T2 DE 69322860 T DE69322860 T DE 69322860T DE 69322860 T DE69322860 T DE 69322860T DE 69322860 T2 DE69322860 T2 DE 69322860T2
Authority
DE
Germany
Prior art keywords
integrin
pct
beta
sec
antibodies against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69322860T
Other languages
English (en)
Other versions
DE69322860D1 (de
Inventor
Kyung Kim
Sarah C Bodary
Anan Chuntharapai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69322860D1 publication Critical patent/DE69322860D1/de
Application granted granted Critical
Publication of DE69322860T2 publication Critical patent/DE69322860T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
DE69322860T 1992-04-03 1993-03-30 Antikörper gegen alpha v beta 3 integrin Expired - Lifetime DE69322860T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86267992A 1992-04-03 1992-04-03
US2591393A 1993-03-03 1993-03-03
PCT/US1993/002987 WO1993020229A1 (en) 1992-04-03 1993-03-30 ANTIBODIES TO ALPHAvBETA3 INTEGRIN

Publications (2)

Publication Number Publication Date
DE69322860D1 DE69322860D1 (de) 1999-02-11
DE69322860T2 true DE69322860T2 (de) 1999-07-01

Family

ID=26700459

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69322860T Expired - Lifetime DE69322860T2 (de) 1992-04-03 1993-03-30 Antikörper gegen alpha v beta 3 integrin

Country Status (8)

Country Link
US (5) US5578704A (de)
EP (1) EP0633945B1 (de)
JP (1) JP3353209B2 (de)
AT (1) ATE175241T1 (de)
AU (1) AU680411B2 (de)
CA (1) CA2132091C (de)
DE (1) DE69322860T2 (de)
WO (1) WO1993020229A1 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770198A (en) * 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US5169930A (en) * 1990-01-05 1992-12-08 La Jolla Cancer Research Foundation Fibronectin receptor
US7132260B2 (en) * 1991-04-05 2006-11-07 The General Hospital Corporation DNA encoding parathyroid hormone receptor
US7150974B1 (en) 1991-04-05 2006-12-19 The General Hospital Corporation Parathyroid hormone receptor binding method
ATE287898T1 (de) * 1991-04-05 2005-02-15 Gen Hospital Corp Parathyroid-hormon-rezeptor und seine kodierende dna
EP0677060A1 (de) * 1993-01-08 1995-10-18 Tanabe Seiyaku Co., Ltd. Die Zell-Adhäsion hemmende Peptide
WO1994018221A1 (en) * 1993-02-02 1994-08-18 The Scripps Research Institute Methods for producing polypeptide binding sites
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US6056958A (en) * 1994-12-09 2000-05-02 Dupont Pharmaceuticals Method of treatment of arterial and venous thromboembolic disorders
DE69531187T2 (de) * 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
CN1226172A (zh) 1996-05-31 1999-08-18 斯克里普斯研究学院 用于抑制血管发生的方法和组合物
WO1998009651A1 (fr) * 1996-09-03 1998-03-12 Chugai Seiyaku Kabushiki Kaisha COMPLEXES D'ANTICORPS ANTI-INTEGRINE α3
EP0846702B1 (de) * 1996-12-09 2009-03-11 MERCK PATENT GmbH Löslicher, rekombinanter alphaV beta3 Adhäsionsrezeptor
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US20010011125A1 (en) * 1997-01-30 2001-08-02 William D. Huse Anti-alpha v beta 3 recombinant human antibodies, nucleic acids encoding same and methods of use
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
DE69828154T2 (de) * 1997-03-12 2005-06-23 Smithkline Beecham Corp. Anti-alphavbeta3 humanizierte monoklonale antikörper
AU6954498A (en) 1997-04-11 1998-11-11 G.D. Searle & Co. Methods for using antagonistic anti-avb3 integrin antibodies
AU6954398A (en) 1997-04-11 1998-11-11 G.D. Searle & Co. Antagonistic anti-avb3 integrin antibodies
US6210904B1 (en) * 1997-10-14 2001-04-03 Merck & Co., Inc. Anticoagulant test
DE19828068C2 (de) * 1998-06-24 2003-12-18 Peter Dietsch Mittel zur spezifischen Hemmung osteoklastärer Knochenresorption
AU3449899A (en) * 1998-08-13 2000-03-06 G.D. Searle & Co. Multivalent avb3 and Metastasis-Associated Receptor Ligands
EP1135688A2 (de) * 1998-12-04 2001-09-26 Novartis AG Verfahren und zusammensetzungen zur gezielten bindung an den alpha(nu)-beta(3) vitronectin rezeptor
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6159443A (en) * 1999-04-29 2000-12-12 Vanderbilt University X-ray guided drug delivery
US7049140B1 (en) 1999-04-29 2006-05-23 Vanderbilt University X-ray guided drug delivery
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US6037176A (en) * 1999-06-25 2000-03-14 Isis Pharmaceuticals Inc. Antisense inhibition of integrin beta 3 expression
CA2383981A1 (en) * 1999-09-08 2001-03-15 Bayer Aktiengesellschaft Integrin-mediated drug targeting
ES2197885T3 (es) * 1999-10-28 2004-01-16 Hofbauer, Reinhold Uso de inhibidores csf-1.
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
EP1297016B1 (de) * 2000-05-12 2006-03-22 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7220824B1 (en) 2000-08-28 2007-05-22 Bayer Aktiengesellschaft Integrin-mediated drug targeting
EP1219305A1 (de) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Konjugate von Integrinrezeptorantagonisten und einem zytostatischen Mittel mit spezifisch spaltbaren Linkergruppen
JP2004536786A (ja) * 2001-03-02 2004-12-09 メディミューン，インコーポレイテッド インテグリンαｖβ３拮抗薬を他の予防薬もしくは治療薬と組み合わせて投与することによる炎症性疾患または自己免疫疾患の予防または治療方法
US7906102B2 (en) 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
US7306925B2 (en) 2001-11-09 2007-12-11 Vanderbilt University Phage antibodies to radiation-inducible neoantigens
EP1487489A4 (de) * 2002-03-04 2008-10-01 Medimmune Inc VERFAHREN ZUR PRÄVENTION ODER BEHANDLUNG VON ERKRANKUNGEN DURCH VERABREICHUNG EINES INTEGRIN avb3 ANTAGONISTEN IN KOMBINATION MIT EINEM HMG-CoA REDUKTASE-HEMMER ODER EINEM BISPHOSPHONAT
CA2478239A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
WO2003086458A1 (en) 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
ATE357255T1 (de) * 2002-06-28 2007-04-15 Vlaams Interuniv Inst Biotech Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
US20050186204A1 (en) * 2002-06-28 2005-08-25 Peter Carmeliet Use of antibodies against FLT-1 for the treatment of osteoporosis
EP1596884A2 (de) * 2003-01-30 2005-11-23 Medimmune, Inc. Verwendung von integrin alphabeta3 antagonisten
KR20110094361A (ko) * 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US20070185077A1 (en) * 2003-07-15 2007-08-09 Washington University Methods of treating, preventing and inhibiting cancer metastasis and tumor formation
US7271245B2 (en) * 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US8187595B2 (en) * 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
JP4928443B2 (ja) * 2004-05-07 2012-05-09 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル インスリン様成長因子ｉを増強または阻害するための方法
NZ604082A (en) 2004-06-04 2014-09-26 Genentech Inc Method for treating multiple sclerosis
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
SI1869085T1 (sl) 2005-03-24 2012-07-31 Thrombogenics Nv Nova anti PLGF protitelesa
US7867490B2 (en) * 2005-06-30 2011-01-11 Vib Vzw Treatment of liver cirrhosis and its complications
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
WO2008008373A2 (en) 2006-07-11 2008-01-17 Arubor Corp Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
WO2008016431A2 (en) * 2006-07-29 2008-02-07 Robert Lamar Bjork Bi-specific monoclonal antibody (specific for both cd3 and cd11b) therapeutic drug
JP2010500360A (ja) 2006-08-10 2010-01-07 アルボア コーポレーション 炎症性サイトカイン阻害剤による下気道炎症疾患の局所療法
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
JP5522717B2 (ja) * 2008-09-19 2014-06-18 国立大学法人佐賀大学 アトピー性皮膚炎の検出方法および予防・治療剤のスクリーニング方法
CN102239178B (zh) 2008-10-02 2017-06-23 Vib研究所 抑制PlGF以治疗费城染色体阳性白血病
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2374002A1 (de) * 2008-12-23 2011-10-12 GE Healthcare UK Limited Anwendung einer auf 99mtc-peptid basierenden verbindung als knochenmark-bildgebungsmittel
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
DK3912643T3 (da) 2009-02-13 2022-10-17 Immunomedics Inc Immunokonjugater med en intracellulært-spaltelig binding
EP2478110B1 (de) 2009-09-16 2016-01-06 Immunomedics, Inc. Klasse-i-anti-cea-antikörper und verwendungen davon
WO2011068845A1 (en) 2009-12-02 2011-06-09 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
EP2704751B1 (de) 2011-05-02 2019-04-17 Immunomedics, Inc. Ultrafiltrationskonzentration ausgewählter allotypen-antikörper für kleinvolumige verabreichung
PL2785739T3 (pl) 2011-12-01 2017-10-31 Thrombogenics Nv Poprawa wyniku trabekulektomii
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
MX2014009043A (es) 2012-01-31 2014-10-14 Genentech Inc Anticuerpos anti-ige y sus metodos de uso.
US9315567B2 (en) 2012-08-14 2016-04-19 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
WO2014036385A1 (en) 2012-08-31 2014-03-06 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (igf-1)
PT2900277T (pt) 2012-12-13 2022-05-25 Immunomedics Inc Doses de imunoconjugados de anticorpos e sn-38 para melhorar a eficácia e diminuir a toxicidade
WO2014130648A1 (en) 2013-02-20 2014-08-28 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
AU2015219495B2 (en) 2014-02-21 2019-11-21 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
EP3160504B1 (de) 2014-06-24 2020-09-16 Immunomedics, Inc. Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis
WO2016014939A1 (en) 2014-07-24 2016-01-28 Washington University Compositions targeting radiation-induced molecules and methods of use thereof
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
EP3316885B1 (de) 2015-07-01 2021-06-23 Immunomedics, Inc. Antikörper-sn-38-immunkonjugate mit einem cl2a-linker
IL293708A (en) 2015-10-06 2022-08-01 Genentech Inc A method for treating multiple sclerosis
EP3207937A1 (de) 2016-02-17 2017-08-23 Royal College of Surgeons in Ireland Verfahren zur behandlung oder prävention von sepsis
KR102101561B1 (ko) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 신생혈관 표적용 조영제 조성물 및 이의 제조방법
CN113557246B (zh) * 2019-07-24 2023-09-01 韩国基础科学支援研究院 靶向αvβ3整联蛋白的单域抗体
CA3208998A1 (en) 2021-01-22 2022-07-28 Steven Kerrigan Treatment of coronavirus
JPWO2022239720A1 (de) 2021-05-10 2022-11-17

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707352A (en) * 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US5306620A (en) * 1987-07-08 1994-04-26 The Scripps Research Institute Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation
EP0341303A4 (de) * 1987-11-19 1990-06-27 Scripps Clinic Res Monoklonaler antikörper gegen den rgd-gerichteten adhäsionsrezeptor von endothelialen zellen.
US5057604A (en) * 1988-08-03 1991-10-15 Washington University Novel monoclonal antibodies
US5169930A (en) * 1990-01-05 1992-12-08 La Jolla Cancer Research Foundation Fibronectin receptor
WO1994018221A1 (en) * 1993-02-02 1994-08-18 The Scripps Research Institute Methods for producing polypeptide binding sites

Also Published As

Publication number Publication date
US5578704A (en) 1996-11-26
JPH07505528A (ja) 1995-06-22
US5652110A (en) 1997-07-29
AU680411B2 (en) 1997-07-31
DE69322860D1 (de) 1999-02-11
CA2132091C (en) 2008-09-16
WO1993020229A1 (en) 1993-10-14
AU3941393A (en) 1993-11-08
EP0633945B1 (de) 1998-12-30
US5652109A (en) 1997-07-29
JP3353209B2 (ja) 2002-12-03
US6369204B1 (en) 2002-04-09
US6359126B1 (en) 2002-03-19
ATE175241T1 (de) 1999-01-15
EP0633945A1 (de) 1995-01-18
CA2132091A1 (en) 1993-10-14

Similar Documents

Publication Publication Date Title
DE69322860T2 (de) Antikörper gegen alpha v beta 3 integrin
DE69321218D1 (de) Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
ATE117434T1 (de) Gefriergetrocknete zusammensetzung, die ein mit meerrettichperoxydase markiertes fab'-fragment eines gegen menschliches beta-interferon gerichteten antikörpers und trehalose enthält; eia kit, der diese zusammensetzung enthält.
ATE157990T1 (de) Monoklonale antikörper gegen den humanen alpha/beta-t-zellenrezeptor, ihre herstellung und verwendung
ES2102007T3 (es) Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras.
DE69328550D1 (de) Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln
DE69026615T2 (de) Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest
FI944509A (fi) Interferonireseptorin vastaisia monoklonaalisia vasta-aineita, joilla on neutralisoivaa aktiivisuutta tyypin I interferonia vastaan
ATE197592T1 (de) Monoklonaler antikörper gegen cd44v6
DE68918497T2 (de) Monoklonale Mäuseantikörper gegen HIV-IP24 und ihre Verwendung in Diagnostika.
NO976122D0 (no) AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes
ES2070488T5 (es) Procedimiento para la diagnosis de enfermedades tumorales.
DE69529272D1 (de) MONOKLONALER ANTIKÖRPER GEGEN DAS HUMANE Mx-PROTEIN MxA
FI86255B (fi) Monoklonal antiurokinase-antikropp, den innehaollande matris och biokemiska testpackningar, i vilka den anvaendes.
DE69524107T2 (de) Bestimmung von freiem und komplexiertem trypsinogen-2
DE69126302T2 (de) Monoklonaler antikörper gegen herzglykosid und dessen verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition